Detalhe da pesquisa
1.
Efficacy of belimumab in patients with systemic lupus erythematosus from North East Asia: Results of exploratory subgroup analyses.
Mod Rheumatol
; 33(4): 751-757, 2023 Jul 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36208293
2.
Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
Mod Rheumatol
; 30(2): 313-320, 2020 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-31199180
3.
Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
Mod Rheumatol
; 29(3): 452-460, 2019 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29792370
4.
A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
Ann Rheum Dis
; 77(3): 355-363, 2018 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29295825
5.
A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
Arthritis Res Ther
; 26(1): 117, 2024 Jun 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-38845046
6.
Phase 3, long-term, open-label extension period of safety and efficacy of belimumab in patients with systemic lupus erythematosus in China, for up to 6 years.
RMD Open
; 8(1)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35428697
7.
The effect of 24-week belimumab treatment withdrawal followed by treatment restart in patients with SLE: an open-label, non-randomised 52-week study.
Arthritis Res Ther
; 24(1): 46, 2022 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35172878
8.
Long-term open-label continuation study of the safety and efficacy of belimumab for up to 7 years in patients with systemic lupus erythematosus from Japan and South Korea.
RMD Open
; 7(2)2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34215703
9.
Safety of Repeated Open-Label Treatment Courses of Intravenous Ofatumumab, a Human Anti-CD20 Monoclonal Antibody, in Rheumatoid Arthritis: Results from Three Clinical Trials.
PLoS One
; 11(6): e0157961, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27336685
10.
Epidemiology and Treatment of New-Onset and Established Rheumatoid Arthritis in an Insured US Population.
Arthritis Care Res (Hoboken)
; 67(12): 1646-55, 2015 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-26097059
11.
Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics.
J Rheumatol
; 40(7): 1089-96, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23729801